Product Program year 2025 Source: CMS Open Payments

Gardasil

Biological Vaccine

NDC 0006-4045-00

Open in the dashboard

General payments

$997,807

47,256 payments

Research payments

$2,694,118

61 payments

Through program year 2025, $997,807 in general payments and $2,694,118 in research payments were reported against Gardasil (Vaccine).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

12 rows
Year Kind Amount Payments
2025 Research $2,508 2
2024 General $931,636 47,220
2024 Research $907,701 14
2023 General $9,500 6
2023 Research $853,044 17
2022 General $23,916 3
2022 Research $54,796 2
2021 General $5,541 3
2021 Research $578,954 21
2020 General $22,492 17
2020 Research $297,115 5
2019 General $4,722 7

Breakdown

Who paid General payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $997,807 47,256 payments
Top recipients General payments · program year 2024
  1. Childrens Hospital Teaching hospital · DC $5,000 <1% · 2 payments
  2. Childrens Hospital Colorado Teaching hospital · CO $3,275 <1% · 2 payments
  3. University Of Iowa Hosp & Clinics Teaching hospital · IA $3,000 <1% · 2 payments
  4. Inova Fairfax Hospital Teaching hospital · VA $2,500 <1% · 1 payment
  5. Abington Memorial Hospital Teaching hospital · PA $2,500 <1% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Pediatrics $230,057 26% · 7,325 practitioners
  2. Family Medicine $170,443 19% · 6,022 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $127,076 14% · 4,798 practitioners
  4. Internal Medicine $90,891 10% · 3,110 practitioners
  5. Physician Assistant $62,831 7% · 2,238 practitioners

The top 5 of 164 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. California $103,012 11% · 2,818 recipients
  2. New York $83,503 9% · 2,335 recipients
  3. Texas $71,507 8% · 2,852 recipients
  4. Florida $62,783 7% · 2,263 recipients
  5. Ohio $46,263 5% · 1,523 recipients

The top 5 of 55 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

6,188

Prescriptions dispensed, refills included

Drug cost

$1,673,759

Paid at the pharmacy, in all

Prescribers

81

With 11 or more claims of it

Medicare Part D drugs matched to GARDASIL, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Gardasil 9 Hpv Vaccine 9-Valent/Pf Similar name 81 6,188 $1,673,759

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 81 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Armaghan Azad Emergency Medicine CA 660 $194,675 None on record
Cedric Davis Family Practice IL 622 $153,654 None on record
Alejandra Moscoso Family Practice TX 282 $67,560 None on record
Ruth Mays Family Practice MI 263 $74,673 None on record
Eldridge Burns Family Practice NE 257 $65,557 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 81 with Patron
47,256 general · 61 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record